NEW YORK, Sep. 11, 2009 (PRNewswire-Asia) -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that the Company has launched a new product called YuYeQingHuo Capsules ("YYQH"). YYQH will be manufactured by the Company's Boke subsidiary, and will be marketed throughout China utilizing AOBO's distribution network, including the Company's national hospital and pharmacy distribution network.

YYQH capsules are a plant-based over the counter medicine used to alleviate pain and inflammation related to laryngitis, acute pharyngitis and acute aphonia. AOBO believes that the market to address laryngitis-related symptoms is currently underserved.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are pleased to demonstrate our new product launch capabilities today. Our extensive network of more than 2,000 sales and marketing professionals, in tandem with our R&D efforts and robust product pipeline, allows AOBO to drive growth from new product sales. This is particularly important as we navigate the changing regulatory landscape in China. We are also excited about today's launch because the YYQH capsules further enhance our market-leading Boke products and brand and we believe that our YYQH capsules address a niche market with no clear market leader as of now. We remain confident in our future growth prospects as we continue to expand our product lines and launch innovative new products."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

SOURCE American Oriental Bioengineering, Inc.